Aid in dying wins approval if patient gives lethal dose

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 1
Volume 18
Issue 1

Oncology News International readers are on the whole in favor of “aid in dying” for terminally ill patients, but diff er on how it should be carried out.

Oncology News International readers are on the whole in favor of “aid in dying” for terminally ill patients, but diff er on how it should be carried out.

In 2008, Washington state passed an initiative that allows doctors to prescribe lethal prescriptions to terminally ill patients who have six months or less to live. The physician must also recommend, but not require, the patient to notify next of kin. The initiative is similar to Oregon’s 1998 Death With Dignity Act.

Of those who responded to the December poll question (“Do you agree with physician-assisted suicide?”), 24% said yes, if physicians determine survival time is less than six months.

Another 24% said yes, if the patient self administers the lethal dose of medication. Finally, 16% voted in favor of having the physician administer the lethal dose.

On the other hand, 16% said no because physician-assisted suicide validates euthanasia while another 16% voted no, not under any circumstances.

See page 2 and visit www.cancernetwork.com to register your vote on this month’s question, “Considering what we know now, should ESAs ever have been approved for chemotherapy-induced anemia?”

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.